Roosevelt Investment Group Inc. grew its stake in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 191.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 64,998 shares of the biopharmaceutical company’s stock after purchasing an additional 42,716 shares during the period. Roosevelt Investment Group Inc.’s holdings in GW Pharmaceuticals PLC- were worth $10,957,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Canada Pension Plan Investment Board lifted its position in GW Pharmaceuticals PLC- by 327.3% during the 4th quarter. Canada Pension Plan Investment Board now owns 1,175,000 shares of the biopharmaceutical company’s stock valued at $114,424,000 after acquiring an additional 900,000 shares during the period. ETF Managers Group LLC purchased a new position in GW Pharmaceuticals PLC- in the fourth quarter worth about $18,150,000. Victory Capital Management Inc. raised its holdings in GW Pharmaceuticals PLC- by 80.4% in the first quarter. Victory Capital Management Inc. now owns 408,940 shares of the biopharmaceutical company’s stock worth $68,935,000 after buying an additional 182,210 shares during the last quarter. Millennium Management LLC purchased a new position in GW Pharmaceuticals PLC- in the fourth quarter worth about $15,685,000. Finally, Jennison Associates LLC grew its stake in shares of GW Pharmaceuticals PLC- by 39.2% in the fourth quarter. Jennison Associates LLC now owns 515,281 shares of the biopharmaceutical company’s stock worth $50,183,000 after acquiring an additional 145,227 shares during the period. 83.37% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Geoffrey W. Dr Guy sold 1,200,000 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.69, for a total value of $17,628,000.00. Following the transaction, the insider now owns 8,465,528 shares of the company’s stock, valued at $124,358,606.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Volker Knappertz sold 12,144 shares of the business’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $14.64, for a total transaction of $177,788.16. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,021,432 shares of company stock valued at $44,883,255. Company insiders own 5.50% of the company’s stock.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.48) by $0.80. The business had revenue of $39.20 million during the quarter, compared to analyst estimates of $12.32 million. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. The company’s revenue was up 1189.5% on a year-over-year basis. During the same period in the prior year, the business posted ($3.12) earnings per share. Equities analysts anticipate that GW Pharmaceuticals PLC- will post -4.76 earnings per share for the current year.
GWPH has been the subject of a number of research analyst reports. Oppenheimer lifted their price target on shares of GW Pharmaceuticals PLC- from $142.00 to $162.00 in a research note on Monday, April 29th. BidaskClub lowered shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. Guggenheim started coverage on shares of GW Pharmaceuticals PLC- in a research report on Friday, February 22nd. They set a “buy” rating and a $178.00 target price for the company. Cantor Fitzgerald restated a “buy” rating and set a $193.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, February 27th. Finally, CIBC upgraded shares of GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a research report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $205.40.
TRADEMARK VIOLATION NOTICE: “Roosevelt Investment Group Inc. Increases Stake in GW Pharmaceuticals PLC- (GWPH)” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/4351571/roosevelt-investment-group-inc-increases-stake-in-gw-pharmaceuticals-plc-gwph.html.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Featured Article: Do back-end load funds outperform no-load funds?
Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.